EANM Marie Curie Award

Therapy with the somatostatin receptor antagonist DOTA-LM3 labeled with terbium-161: Interim results of the Phase 0 Study in patients with gastroenteropancreatic neuroendocrine tumors

J.Fricke¹, F. Westerbergh², L. McDougall¹, C. Favaretto^1,3, E. Christ^4,5, G. Nicolas¹, S. Geistlich³, F. Borgna³, M. Fani¹, P. Bernhardt^2,6, N. van der Meulen³, C. Müller^3,7, R. Schibli^3,7, D. Wild^1,5;

¹Division of Nuclear Medicine, University Hospital Basel, Basel, SWITZERLAND, ²Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN, ³Center for Radiopharmaceutical Sciences, Paul Scherrer Institute (PSI), Villigen-PSI, SWITZERLAND, ⁴Division of Endocrinology, University Hospital Basel, Basel, SWITZERLAND, ⁵ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, SWITZERLAND, ⁶Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, SWITZERLAND, ⁷Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, SWITZERLAND.

© Faistauer Photography

Molecular imaging predicts response absence to T-DM1 in advanced HER2-positive breast cancer: final results from a prospective phase II ZEPHIR trial

Mileva¹, E. G. de Vries², T. Guiot³, Z. Wimana⁴, A. Deleu¹, C. Schröder^5,6, Y. Lefebvre¹, M. Paesmans⁷, S. Stroobants⁸, M. Huizing⁹, P. Aftimos¹⁰, J. Tol¹¹, W. Van der Graaf¹², W. Oyen^13,14,15, D. Vugts¹⁶, C. Menke-van der Houven van Oordt¹², A. Brouwers¹⁷, M. Piccart-Gebhart¹⁰, P. Flamen¹, G. Gebhart¹;

¹Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ²Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, Groningen, NETHERLANDS, ³Department of Medical Physics, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ⁴Department of Radiopharmacy, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ⁵Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, ⁶Department of Medical Oncology, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, NETHERLANDS, ⁷Data center, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ⁸Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Antwerp, BELGIUM, ⁹Department of Medical Oncology, Antwerp University Hospital, Edegem, Antwerp, BELGIUM, ¹⁰Department of Medical Oncology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ¹¹Department of Internal Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, the Netherlands, Den Bosch, NETHERLANDS, ¹²Department of Medical Oncology, Amsterdam UMC location VUMC, Cancer Centre Amsterdam, Amsterdam, NETHERLANDS, ¹³Humanitas Clinical and Research Center, Humanitas University, Milan, ITALY, ¹⁴Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, NETHERLANDS, ¹⁵Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, NETHERLANDS, ¹⁶Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, NETHERLANDS, ¹⁷Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS.

[¹⁸F]AlF-NOTA-octreotide vs. [⁶⁸Ga]Ga-DOTA-somatostatin analogue PET in neuroendocrine tumour patients: final results of a prospective multicentre trial

E. Pauwels¹, F. Cleeren², T. Tshibangu², M. Koole¹, K. Serdons¹, L. Boeckxstaens¹, J. Dekervel³, T. Vandamme^4,5, W. Lybaert⁵, B. Van den Broeck⁶, P. M. Clement⁷, K. Geboes⁸, E. Van Cutsem³, S. Stroobants⁹, C. Verslype³, G. Bormans², C. M. Deroose¹;

¹Nuclear Medicine, University Hospitals Leuven; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM, ²Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, BELGIUM, ³Digestive Oncology, University Hospitals Leuven, Leuven, BELGIUM, ⁴Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, BELGIUM, ⁵Oncology, NETwerk Antwerpen-Waasland CoE, Antwerpen, BELGIUM, ⁶Nuclear Medicine, Ghent University Hospital, Ghent, BELGIUM, ⁷General Medical Oncology, University Hospitals Leuven, Leuven, BELGIUM, ⁸Digestive Oncology, Department of Gastroenterology, Ghent University Hospital, Ghent, BELGIUM, ⁹Nuclear Medicine, Antwerp University Hospital; Molecular Imaging and radiology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, BELGIUM.

Enhanced Therapeutic Effect of the Albumin-Binding [177Lu]Lu-Ibu-DAB-PSMA as Compared to [177Lu]Lu-PSMA-617 – A Preclinical Therapy Study

V. Tschan¹, F. Borgna¹, R. Schibli^1,2, C. Müller^1,2;

¹Paul Scherrer Institute, 5232 Villigen-PSI, SWITZERLAND, ²ETH Zurich, 8093 Zurich, SWITZERLAND.

Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: results of a phase 2 trial

G. Paganelli¹, S. Severi¹, M. Sansovini¹, S. Nicolini¹, I. Grassi¹, F. von Eyben², V. Conteduca¹, M. Monti¹, F. Foca¹, G. Gurioli¹, M. Celli¹, F. Matteucci¹, U. De Giorgi¹;

¹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST IRCCS, Meldola (FC), ITALY, ²Center of Tobacco Control Research, Odense M, DENMARK.

Changes in synaptic density in relation to tau deposition in prodromal Alzheimer’s disease: a dual protocol PET-MR study

C. H. R. J. Vanhaute¹, J. Ceccarini², L. Michiels³, S. Sunaert⁴, R. Lemmens³, L. Emsell⁴, M. Vandenbulcke⁵, K. Van Laere²;

¹Nuclear Medicine and molecular imaging, Department of Geriatric Psychiatry, University Hospitals Leuven; department of imaging and pathology, Catholic University Leuven, Leuven, BELGIUM, ²Nuclear Medicine and molecular imaging, University Hospitals Leuven; department of imaging and pathology, Catholic University Leuven, Leuven, BELGIUM, ³Department of Neurology, University Hospitals Leuven; Laboratory for neurobiology, Catholic University Leuven; Center for Brain and disease research, VIB-KU Leuven, Leuven, BELGIUM, ⁴Department of Imaging and pathology, Translational MRI; Catholic University Leuven, Leuven, BELGIUM, ⁵Department of Geriatric Psychiatry, University Hospitals Leuven, Leuven, BELGIUM..

Terbium-161 for PSMA-Targeted Radionuclide Therapy of Prostate Cancer

C. Mueller¹, C. A. Umbricht¹, N. Gracheva¹, V. J. Tschan¹, G. Pellegrini², P. Bernhardt³, J. R. Zeevaart⁴, U. Koester⁵, R. Schibli¹, N. P. van der Meulen¹;

¹Paul Scherrer Institute, Villigen-PSI, SWITZERLAND, ²Vetsuisse Faculty, University of Zurich, Zurich, SWITZERLAND, ³University of Gothenburg, Gothenburg, SWEDEN, ⁴Necsa, Pretoria, SOUTH AFRICA, ⁵Insitut Laue-Langevin, Grenoble, FRANCE.

PSMA-targeting alpha-Radiation therapy with 225Actinium-PSMA-617: Dosimetry, toxicity and duration of tumor-control

C. Kratochwil¹, F. Bruchertseifer², F. L. Giesel¹, C. Apostolidis², U. Haberkorn¹, A. Morgenstern²;

¹University Hospital Heidelberg, Heidelberg, GERMANY, ²EC-JRC, Directorate for Nuclear Safety and Security, Karlsruhe, GERMANY.

Secondary glioblastoma multiforme – local alpha emiters targeted therapy with 213Bi-DOTA-substance P

L. Królicki¹, A. Morgenstern², J. Kunikowska¹, H. Koziara³, B. Królicki³, M. Jakuciński⁴, D. Pawlak⁵, C. Apostolidis², F. Bruchertseifer²;

¹ Department of Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland, ² European Commission, Joint Research Centre, Institute for Transuranium Elements, Karlsruhe, Germany, ³ Department of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland, ⁴ Department of Nuclear Medicine, Brodnowski Hospital, Warsaw, Poland, ⁵ Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, POLAND.

Feasibility of Affibody molecule-based PNA-mediated pretargeting

A. Honarvar et al.,

Uppsala University, Uppsala, SWEDEN.

Visualising Parasympathetic Denervation in Parkinson’s Disease – [11C]donepezil PET for Imaging Acetylcholinesterase Density in Peripheral Organs (Part I)

P. Borghammer et al.Aarhus University Hospital, Aarhus, DENMARK.

A new route toward enhancing the uptake of [111In/177Lu-DOTA,Leu15]MG11 in CCK2R-positive xenografts in mice

A. Kaloudi¹, B. A. Nock¹, E. Lymperis¹, P. J. Marsouvanidis¹,², E. P. Krenning², M. de Jong²,³, T. Maina-Nock¹;¹Molecular Radiopharmacy, INRASTES, NCSR Demokritos, Athens, GREECE, ²Department of Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS, ³Department of Radiology, Erasmus MC, Radiology, NETHERLANDS.

Detection of prostate cancer using 68Ga-labelled bombesin analogue BAY 86-7548 in patients undergoing radical prostatectomy

H. Minn^2,5, E. Kähkönen¹, I. Jambor^2,3, J. Kemppainen^2,4, K. Lehtiö⁵, J. Silén², A. Kuisma⁵, P. Luoto², T. Tolvanen², K. Alanen⁶, T. Grönroos², M. Kallajoki⁶, A. Roivainen², N. Schäfer⁷, R. Schibli⁸, M. Dragic⁸, A. Johayem⁹, R. Valencia¹⁰, S. Borkowski¹⁰;¹Department of Surgery, Division of Urology, Turku University Hospital, Turku, Finland, ²Turku PET Centre, University of Turku, Turku, Finland, ³Department of Diagnostic Radiology, University of Turku, Turku, Finland, ⁴Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland, ⁵Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland, ⁶Department of Pathology, Turku University Hospital, Turku, Finland , ⁷Department of Medical Oncology and Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland, ⁸Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland , ⁹Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland, ¹⁰Bayer Pharma AG, Berlin, Germany

Longitudinal imaging of transplanted islets in a rat model with SPECT

K. Andralojc, M. Brom, L. Claessens-Joosten, D. Bos, W. Oyen, O. Boerman, M. Gotthardt;Radboud University & Medical Center Nijmegen, NETHERLANDS

VEGF Immuno-PET with 89Zr-ranibizumab during sunitinib treatment

M. N. Lub-de Hooge, W. B. Nagengast, J. A. Gietema, S. F. Oosting, M. A. de Korte, F. Warnders, H. Timmer-Boscha, G. A. Hospers, J. R. de Jong, W. F. den Dunnen, H. Hollema, R. A. J. O. Dierckx, E. G. E. de Vries;University Medical Center Groningen, Groningen, NETHERLANDS

Development of an improved amyloid probe, [11C]AZD2184. From pre-clinical to clinical in vivo PET measurements in AD patients

J. Andersson1, K. Varnäs¹, Z. Cselényi², B. Gulyás¹, B. Swahn³, S. Finnema¹, S. Nyberg², L. Farde², C. Halldin¹;¹Karolinska Institutet, Stockholm, SWEDEN, ²AstraZeneca Pharmaceuticals Neuroscience Clinical, Södertälje, SWEDEN, ³Department of Medicinal Chemistry AstraZeneca R&D, Södertälje, SWEDEN

Intravesical α-radioimmunotherapy with Bi-213-anti-EGFR-MAb defeats human bladder carcinoma in xenografted nude mice

B. Pfost¹, C. Seidl¹, M. Autenrieth², D. Saur³, F. Bruchertseifer⁴, A. Morgenstern⁴, M. Schwaiger¹, R. Senekowitsch-Schmidtke<sup>1

1</sup>Department of Nuclear Medicine, Technische Universität München, München, GERMANY, ²Department of Urology, Technische Universität München, München, GERMANY, ³II. Medizinische Klinik und Poliklinik, Technische Universität München, München, GERMANY, ⁴European Commission, JRC, Institute for Transuranium Elements, Karlsruhe, GERMANY

Converging evidence for specific neurotoxic effects of ecstasy on the thalamus: [123I]β-CIT SPECT and advanced MRI studies

M. de Win et al.University Hospital Amsterdam, Amsterdam, The Netherlands

Early predictive value of positron emission tomography with [18F]-fluorodeoxyglucose for the pathologic complete response of primary tumor in breast cancer patients treated by neoadjuvant chemotherapy

A. Berriolo-Riedinger et alCentre G.F. Leclerc, Dijon, France

A comparison of amphetamine induced changes in agonist and antagonist radioligand binding potential on the dopamine D2 receptor in primate brain

N. Seneca, S. Finnema, M. Ichise, B. Gulyas, H. Wikstrom, R. Innis, L. Farde, C. Halldin (Stockholm, Bethesda, Groningen)

^99mTC Interleukin-2 (^99m TC-IL2) Scintigraphy for Imaging Vulnerable Atherosclerotic Plaques

A. Signore, A. Annovazzi, E. Bonnano, M. Arca, C. D’Alessandria, A. Marcoccia, L. Spagnoli, F. Violi, F. Scopinaro, G. De Toma (Rome)

Radioimmunotherapy with Lutetium-177-DOTA-Rituximab: a Phase I/II-Study in Patients with Follicular and Mantle Cell Lymphoma. An interim Analysis

F. Forrer, A. Lohri, H.Uusijärvi, G. Moldenhauer, J. Chen, R. Herrmann, E. Nitzsche, H. Mäcke, J.Müller-Brand (Basel, Liestal, Gothenburg)

Combined [11C]Raclopride-PET and voxel based morphometry analysis in early Huntington´s disease: separating between functional and morphological alterations

F.D. Juengling, J. Karitzky, C. Solbach, J. Kassubek, C. Saft, B. Heinen, S.N. Reske, T. Kioschies, K. Henkel (Ulm)

[11C]MADAM – a highly suitable radioligand for examination of the serotonin transporter with PET

C. Halldin, D. Guilloteau, J. Tarkiainen, J. Sóvágó, B. Gulyás, J. Sandell, P. Emond, J. Vercouillie, S. Chalon, J. Hiltunen, L. Farde

Partial reversibility and gender differences in the toxic effects of MDMA (‘ecstasy’) on brain serotonin neurons

L. Renemann, J. Booij , K. De Bruin , F.A. De Wolff , W. van den Brink, G.J. Den Heeten (Amsterdam)

Low- versus high-dose radioimmunotherapy with humanized anti-CD20 antibodies in a broad spectrum of B-cell associated malignancies

T.M. Behr , B. Wörmann, M. Gramatzki, M. Béhé, F. Griesinger, W. Hiddemann, D.M. Goldenberg, W. Becker (Göttingen)

Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer

G. Paganelli, C. DeCicco , M. Cremonesi, A. Luini, M. Bartolomei, C. Grana , G. Prosco , V. Galimberti, P. Calza, G. Viale, U. Veronesi (Milan)

Coronary revascularization improves survival and left ventricular function in patients with chronic coronary artery disease and dysfunctional but viable myocardium at thallium-201 imaging

A. Cuoculo, E. Nicolai, M. Petretta, L. Pace, S. Cardei, A. Varrone, B. Trimarco, M. Salvatore (Naples)

Relationship between clinical features of Parkinson’s disease and presynaptic dopamine transporter function assessed with I-123 IPT and SPECT

K. Tatsch, P.D. Mozley, J. Schwarz, R. Linke, O. Pogarell, R.S. Fieber, K. Hahn, H.F. Kung (Munich)

Imaging of 5-HT1a receptors in human brain using (C-11)Way-100635 and PET

V. Pike, J. McCarron, S. Hume, S. Ashworth, J. Opcka-Juffry, A. Lammerstma, K. Poole, A. Malizia, C. Bench, P. Grasby, I. Cliffe, A. Fletcher (London)

Recombinant human interleukin-1: a potential agent to image infectious foci

J. van der Laken, I.C. Boerman, W.J.G. Oyen, M.T.P. van de Ven, J. Makarewicz, R.A.M.J. Claessens, J.W.M. van der Meer, F.H.M. Corstens (Nijmegen)

Comparison of 123-I-alpha-methyl tyrosine SPECT and 11C-L-methionine PET in patients with brain tumors: initial results

K.J. Langen, B. Hamacher, K. Ziemons, T. Kuwert, U. Braun, H. Herzog, J.C.W. Kiwit, B. Nebeling, G. Stöcklin, H.W. Müller- Gärtner (Düsseldorf, Jülich)

Preparation of (11C)ß-CIT, a new ligand for imaging cocaine binding sites in vivo by PET

C. Halldin, L. Farde, L. Müller, P. Karlsson, J.L. Neumeyer, Y. Gao, R. Milius, H. Hall, C.G. Swahn (Stockholm, Natick)

PET studies of human cerebral malignancy with (2-11C) thymidine (TRD) and (18F)FDG

T. van der Borght, S. Pauwels, L. Lambotte, L.D. Labor, S. De Maeght, G. Stroobandt, C. Laterre (Brussels)

Ventilation and perfusion in a single image

J.J.P. de Lima, M.F.R. Botelho, A.M.S. Pereira, J.A.S. Rafael, M.A.T. Marques, A.J. Pinto, F. Godinho, M.C. Pereira, M.F. Baganha (Aveiro, Coimbra, Lisbon)